Cardiac Risk Higher With Rosiglitazone Than Pioglitazone
March 17, 2011|Hospitalist News (Archived)
Author and Disclosure Information
Major Finding: Patients taking rosiglitazone had significantly increased risks of myocardial infarction (odds ratio, 1.16), heart failure (OR, 1.22), and death (OR, 1.14), compared with those taking pioglitazone.
Data Source: A meta-analysis of 16 studies in 810,000 thiazolidinedione users.
Disclosures: Dr. Loke and his colleagues declared no conflicts of interest in their meta-analysis.
FROM BMJ
Dr. Loke and his colleagues declared no conflicts of interest in their meta-analysis. Dr. Montori and Dr. Shaw reported having no competing interests. Dr. Kaul also disclosed none related to his conclusions.
